LexisPSL
Crucial Development on the Presumption of Confidentiality in the Access to Document Saga (PTC Therapeutics v EMA and MSD Animal Health Innovation, Intervet v EMA)
September 19, 2019
The saga of access to documents (ATD) cases in the European pharmaceutical legal landscape continues, this time with two promising opinions of Advocate-General Hogan. In summary AG Hogan found that the General Court had erred in law in its conclusions that (a) there was no general presumption of confidentiality and (b) access to the study reports submitted in a marketing authorisation application dossier at issue would not compromise the applicants’ commercial interests.
This article has been originally published on LexisPSL.
Contacts

Capabilities
Suggested News & Insights
Bay Area Life Sciences RoundtableWednesday, July 22, 2026Sidley Sponsors the 2026 EU Pharma Law ForumTuesday, May 19, 2026 – Thursday, May 21, 2026Women’s Life Sciences Network – Biotech Act: Funding and Investment OpportunitiesTuesday, May 19, 2026Growth Meets Guardrails: Getting You Ready for the New Realm of Ad/PromoWednesday, May 13, 2026Global Trial Expansion — Key Considerations for EU/U.S. SponsorsApril 21, 2026U.S. FDA Issues First Drug Supply Chain Security Act Warning Letter Targeting a Dispenser, Signaling Expanded Enforcement FocusApril 15, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory
